Cumulative-incidence crossover and conditional mortality after definitive surgery for endometrial cancer: a population-based competing-risk analysis
Abstract
Long-term survivors of endometrial cancer face competing risks from cancer and other conditions, but how these risks evolve remains uncertain. We conducted a population-based retrospective cohort study of 255,104 women who underwent hysterectomy-based definitive surgery for endometrial cancer in the Surveillance, Epidemiology, and End Results Program (2000–2021). Cause-specific cumulative incidence was estimated using Aalen–Johansen methods. Crossover was the earliest month when composite non-endometrial mortality (cardiovascular, other malignant cancer, or other non-cancer death) exceeded endometrial cancer-specific mortality and remained higher for 12 months. During a median follow-up of 8.2 years, 62,347 deaths occurred. Endometrial cancer mortality was 6.2%, 7.1%, and 7.4% at 5, 10, and 15 years, compared with 5.3%, 16.6%, and 28.3% for composite non-endometrial mortality. Crossover occurred at 5.6 years (95% confidence interval, 5.4–5.8) overall but was not reached within 15 years for stage III/IV disease or chemotherapy recipients. Among 10-year survivors, subsequent 5-year mortality was 0.4% from endometrial cancer and 15.3% from non-endometrial causes; cardiovascular mortality remained elevated relative to U.S. female rates (standardized mortality ratio, 1.21; 95% confidence interval, 1.16–1.26). These findings support integrated cardiovascular and metabolic risk management from diagnosis alongside individualized, guideline-concordant oncologic surveillance.
Related
- Cumulative average glucose–lipid metabolic obesity index associates with benign prostatic hyperplasia incidence in Chinese middle-aged and older men
- Invasive Aspergillosis Complicating Severe COVID-19: Cumulative Incidence, Risk Factors, and Outcomes Between the First Wave of the Pandemic and Subsequent Waves, According to the ECMM/ISHAM Classification and a Local Case Assessment
- Activity Limitation, Health-Care Use, and Unmet Need Among Korean Adults: Cumulative and Conditional Cardiometabolic Care Cascades.
- Cumulative incidence and factors associated with unfavorable tuberculosis treatment outcomes among people living with HIV in Liangshan, China: a competing-risk analysis
- Risk factors for endometrial cancer incidence and regional and ethnic disparities in the USA.
BibTeX
@article{wang2026cumulativeincidence,
title = {{Cumulative-incidence crossover and conditional mortality after definitive surgery for endometrial cancer: a population-based competing-risk analysis}},
author = {Ruicong Wang and Chuanjia Guo and Fang Tong},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-71645-5},
url = {https://www.nature.com/articles/s41598-026-71645-5},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cumulative-incidence crossover and conditional mortality after definitive surgery for endometrial cancer: a population-based competing-risk analysis
AU - Ruicong Wang
AU - Chuanjia Guo
AU - Fang Tong
PY - 2026
DA - 2026/10/01
JO - Scientific Reports
DO - 10.1038/s41598-026-71645-5
UR - https://www.nature.com/articles/s41598-026-71645-5
AB - Long-term survivors of endometrial cancer face competing risks from cancer and other conditions, but how these risks evolve remains uncertain. We conducted a population-based retrospective cohort study of 255,104 women who underwent hysterectomy-based definitive surgery for endometrial cancer in the Surveillance, Epidemiology, and End Results Program (2000–2021). Cause-specific cumulative incidence was estimated using Aalen–Johansen methods. Crossover was the earliest month when composite non-endometrial mortality (cardiovascular, other malignant cancer, or other non-cancer death) exceeded endometrial cancer-specific mortality and remained higher for 12 months. During a median follow-up of 8.2 years, 62,347 deaths occurred. Endometrial cancer mortality was 6.2%, 7.1%, and 7.4% at 5, 10, and 15 years, compared with 5.3%, 16.6%, and 28.3% for composite non-endometrial mortality. Crossover occurred at 5.6 years (95% confidence interval, 5.4–5.8) overall but was not reached within 15 years for stage III/IV disease or chemotherapy recipients. Among 10-year survivors, subsequent 5-year mortality was 0.4% from endometrial cancer and 15.3% from non-endometrial causes; cardiovascular mortality remained elevated relative to U.S. female rates (standardized mortality ratio, 1.21; 95% confidence interval, 1.16–1.26). These findings support integrated cardiovascular and metabolic risk management from diagnosis alongside individualized, guideline-concordant oncologic surveillance.
SN - 2045-2322
ER -